Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
